Signalife, Inc.
OTC Bulletin Board : SGAL

November 10, 2008 16:30 ET

Legend Willie Gault Becomes Signalife's Co-CEO; Company Changing Name to HeartTronics, Inc.

LOS ANGELES, CALIFORNIA--(Marketwire - Nov. 10, 2008) - Signalife, Inc. (OTCBB:SGAL) announced today that Willie Gault - whose passion has led to the formation of Athletes for Life - the non-profit charity who sponsored heart screenings at which the lives of patients across the country have been saved, including 16-year old high school athlete Josh Nails - has been appointed co-CEO of the Company to handle all operations. On behalf of investors as well as individually, Mr. Gault has achieved numerous large mergers and acquisitions in various industries throughout the 50-United States, and manages these investment interests for a vast array of clients nationally and internationally. Prior to that, Mr. Gault was a member of the Super Bowl Champion Chicago Bears and has set and broken numerous track and field records over what now spans a 30-year athletic career.

The Company also announced that it is changing its name and marks, commensurate with the extensive screenings and Company peer supervision now being done to assist in the eradication of sudden heart attack and late stage heart disease. The new corporate name will be HeartTronics, Inc. and the new logo shall be available for viewing on the Company's website later this week. The name of the Company will be formally changed to HeartTronics, Inc. with the State of Delaware 20 days after the Company mails an information circular to its shareholders. The trading symbol and CUSIP number for the Company's stock will be concurrently changed, with the OTCBB designating the new trading symbol on the day the name change is effectuated with the Delaware Secretary of State. The Company will provide additional information on the effective date of the name change and new trading symbol and CUSIP number concurrent with the designation of a new trading symbol by the OTCBB.

Rowland Perkins, the Company's co-CEO for Administrative matters, commented: "I have never met a person besides Willie Gault who has the energy and passion toward this worthy cause of stopping the ravage of sudden cardiac death and late stage heart disease. As we have now learned, the Fidelity 100 is the only device capable of detecting the full bandwidth of pathology recommended by the American Heart Association. I am pleased that Willie has now come aboard to increase the screenings nationwide and to make them available not only to the poor (through AFL) but to affluent communities as well. Heart disease does not distinguish. It kills our citizens irrespective of socio-economic bracket, race or gender."

Mr. Gault's initial salary shall be $1.00 per annum, until the Company is profitable.

Mr. Gault also commented: "I am honored to take on this position. Every person deserves not to die suddenly. In no other disease state can it be said that "this disease can kill instantly." The exception is stroke, however, even that can be prevented by good comprehensive physician-screenings. My goal as HeartTronics' Operational CEO is to bring our abilities and technologies to all communities - affluent and (through AFL) impoverished alike. With physician's use of our Fidelity 100 heart monitor, I have seen with my own eyes and felt with my own heart the phenomenon of a life being saved. It means something to me, because my best friends - from Reggie White to Todd Bell - died at the hands of the same evil fate. Now it is time to get on with helping all of our citizenry, and in stopping disinformation from the health care community to the effect that everything is "alright," when the costs for heart disease are increasing another $50 billion this year according to the United States Government (now a staggering $450 billion spent in the United States alone, much of which is paid by Medicare). I am working closely with the public, private and philanthropic sectors to put a stop to the nonsense."

"There are lots of heart devices out there, from arrhythmia machines to CT scans. They do nothing to provide a comprehensive screening nor to lessen the cost-and-life impact of this disease. The other devices do not even claim to assist in the problem, and that is why the figures increase by tens of billions of dollars per year. These numbers are being paid out by our federal and state governments, and by the American population. I can guarantee everybody that the governments are "on to it" and actual prevention will be the wave of the future. The Fidelity 100 weighs a few pounds and is the only device capable of testing across the full range of disease-states, and in ambulatory settings as well. Please get ready when our screenings come to a hospital or facility near you."

About HeartTronics, Inc.

HeartTronics, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. The Company uses its patented signal technology to design and develop medical devices - two of which are FDA-cleared - as well as therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

HeartTronics, Inc. is publicly traded OTC Bulletin Board and the Pink Sheets under the symbol SGAL. The website for the company is Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause HeartTronics' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating HeartTronics' technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating HeartTronics' technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating HeartTronics' technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring, the compliance with purchase orders, payment for parts making up orders receiving by the Company and other biomedical devices incorporating HeartTronics' technology. Additionally, HeartTronics - in its prior name (Signalife) - has been sued in various class action lawsuits and has filed a lawsuit against alleged naked short sellers (and others, including the plaintiff's counsel in one class action matter), some of whom have since gone out of business for alleged naked short selling and other risky derivatives trading. These matters may negatively impact the Company or - possibly - may have the reverse impact. The Company and certain of its agents and prior agents are represented in defense of the class action lawsuits - and perhaps in other matters from time to time - by the national law firm of Akin Gump Strauss Hauer & Feld LLP with respect to these matters. While the Company believes these class action lawsuits lack merit and may be frivolous, the presence of the matters creates an obvious risk to the Company. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in HeartTronics' filings with the Securities and Exchange Commission.

Contact Information

  • Signalife, Inc.
    Willie Gault
    (818) 432-4560